Arbor Biotechnologies is a next-generation gene editing company founded in 2016 by Feng Zhang, David Walt, David Scott and Winston Yan, and headquartered in Cambridge, Massachusetts. Its proprietary AI- and machine-learning-guided discovery engine has produced a toolbox of programmable DNA editors spanning knockdown, nuclease excision and compact reverse-transcriptase editing, aimed at functionally curative genomic medicines. The wholly-owned pipeline is focused on liver disease (ABO-101 for primary hyperoxaluria type 1 and ABO-103, both LNP-delivered and partnered with Chiesi Group) and CNS disease (ABO-202, ABO-203 and ABO-204 for ALS, plus ABO-206, all AAV-delivered), alongside collaborative ex vivo cell therapy programs run with Vertex, Allogene, Edigene and Chiesi. Investors include ARCH Venture Partners, Ally Bridge Group, Temasek, TCG and the Samsung Life Science Fund. Arbor operates no product or developer API and publishes no developer portal, SDKs or API documentation; its corporate site does serve the standard WordPress REST API anonymously, which makes its press releases, site pages and taxonomies machine-readable.
Arbor Biotechnologies publishes 1 API on the APIs.io network: Content API (WordPress REST). Tagged areas include Company, Biotechnology, Gene Editing, CRISPR, and Genomic Medicine.
Arbor Biotechnologies’ developer surface includes engineering blog, support, and 22 more developer resources.
Read-only, anonymously accessible WordPress REST API served by the Arbor Biotechnologies corporate site at https://arbor.bio/wp-json. It exposes the company's press releases and...
aid: arbor-biotechnologies
name: Arbor Biotechnologies
description: Arbor Biotechnologies is a next-generation gene editing company founded in 2016 by Feng Zhang, David Walt, David
Scott and Winston Yan, and headquartered in Cambridge, Massachusetts. Its proprietary AI- and machine-learning-guided discovery
engine has produced a toolbox of programmable DNA editors spanning knockdown, nuclease excision and compact reverse-transcriptase
editing, aimed at functionally curative genomic medicines. The wholly-owned pipeline is focused on liver disease (ABO-101
for primary hyperoxaluria type 1 and ABO-103, both LNP-delivered and partnered with Chiesi Group) and CNS disease (ABO-202,
ABO-203 and ABO-204 for ALS, plus ABO-206, all AAV-delivered), alongside collaborative ex vivo cell therapy programs run
with Vertex, Allogene, Edigene and Chiesi. Investors include ARCH Venture Partners, Ally Bridge Group, Temasek, TCG and
the Samsung Life Science Fund. Arbor operates no product or developer API and publishes no developer portal, SDKs or API
documentation; its corporate site does serve the standard WordPress REST API anonymously, which makes its press releases,
site pages and taxonomies machine-readable.
url: https://raw.githubusercontent.com/api-evangelist/arbor-biotechnologies/refs/heads/main/apis.yml
image: https://arbor.bio/wp-content/uploads/Transparent-Color-Logo-1.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline-2026-07-31
x-sector: biotechnology
x-api-posture: no-product-api
specificationVersion: '0.20'
created: '2026-07-31'
modified: '2026-07-31'
tags:
- Company
- Biotechnology
- Gene Editing
- CRISPR
- Genomic Medicine
- Life Sciences
- Drug Development
- Clinical Trials
- Neurology
- Rare Disease
- Healthcare
- Private Company
apis:
- aid: arbor-biotechnologies:arbor-biotechnologies-content-api
name: Arbor Biotechnologies Content API (WordPress REST)
description: 'Read-only, anonymously accessible WordPress REST API served by the Arbor Biotechnologies corporate site at
https://arbor.bio/wp-json. It exposes the company''s press releases and announcements (59 posts, 2018-2026), the 11 static
site pages covering the pipeline, platform, leadership and clinical program, 11 categories, the media library, cross-content
search, oEmbed and Yoast SEO / schema.org metadata. This is an incidental content management surface, not a first-party
API product: Arbor publishes no developer documentation, issues no keys, offers no SDKs or support channel for it, and
every write, user, settings, plugin, theme and site-health route returns 401 to anonymous callers while comments return
403.'
humanURL: https://arbor.bio/stay-updated/
baseURL: https://arbor.bio/wp-json
tags:
- Content
- Press Releases
- WordPress
- CMS
properties:
- type: OpenAPI
url: openapi/arbor-biotechnologies-content-openapi.yml
- type: Overlay
url: overlays/arbor-biotechnologies-content-overlay.yaml
- type: Authentication
url: authentication/arbor-biotechnologies-authentication.yml
- type: Conventions
url: conventions/arbor-biotechnologies-conventions.yml
- type: ErrorCatalog
url: errors/arbor-biotechnologies-problem-types.yml
- type: DataModel
url: data-model/arbor-biotechnologies-data-model.yml
- type: Lifecycle
url: lifecycle/arbor-biotechnologies-lifecycle.yml
- type: Conformance
url: conformance/arbor-biotechnologies-conformance.yml
- type: AgentSkill
url: skills/_index.yml
- type: APIReference
url: https://developer.wordpress.org/rest-api/reference/
- type: BlogRSS
url: https://arbor.bio/feed/
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/arbor-biotechnologies-domain-security.yml
- type: Website
url: https://arbor.bio/
- type: Blog
url: https://arbor.bio/stay-updated/
- type: BlogRSS
url: https://arbor.bio/feed/
- type: About
url: https://arbor.bio/who-we-are/
- type: Founders
url: https://arbor.bio/who-we-are/founders/
- type: Leadership
url: https://arbor.bio/who-we-are/leadership/
- type: Investors
url: https://arbor.bio/who-we-are/investors/
- type: Partners
url: https://arbor.bio/who-we-are/partnerships/
- type: Technology
url: https://arbor.bio/what-we-do/
- type: Publications
url: https://arbor.bio/what-we-do/scientific-publications/
- type: Pipeline
url: https://arbor.bio/pipeline/
- type: ClinicalTrials
url: https://arbor.bio/clinical-trial/
- type: Careers
url: https://arbor.bio/inside-arbor/careers/
- type: Contact
url: https://arbor.bio/get-in-touch/
- type: Support
url: https://arbor.bio/get-in-touch/
- type: PrivacyPolicy
url: https://arbor.bio/privacy-policy/
- type: TermsOfService
url: https://arbor.bio/terms-of-use/
- type: SiteMap
url: https://arbor.bio/site-map/
- type: LinkedIn
url: https://www.linkedin.com/company/arborbio
- type: Twitter
url: https://twitter.com/arbortx
- type: SecondaryMarket
url: https://forgeglobal.com/arbor-biotechnologies_stock/
- type: AgentSkill
url: skills/_index.yml
- type: LLMsTxt
url: llms/arbor-biotechnologies-llms.txt
x-enrichment:
date: '2026-07-31'
status: enriched
artifacts_added: 12
pass: local-v1
notes: No product API. Contract discovery probed arbor.bio and www.arbor.bio plus eight non-resolving subdomains (api, developer,
docs, status, trust, mcp, app, portal) for OpenAPI, GraphQL, MCP tools/list, A2A agent cards and the full /.well-known/
set — all 404 or NXDOMAIN. The one real machine-readable contract found is the site's anonymous WordPress REST API at
https://arbor.bio/wp-json (18 namespaces, 341 declared routes); an OpenAPI 3.1 covering 21 individually verified anonymous
read operations was derived from that live route index. No packages, MCP server, agent card, OAuth scopes, vulnerability-disclosure
programme or trust center exist; those artifacts were deliberately not written rather than stubbed, and no WellKnown pointer
was emitted because every /.well-known/ probe returned 404.
Kin Score
How this is scored →